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ABSTRACT
The role of drug pressure on the replicative capacity of protease inhibitor-resistant HIV-1 variants and
the contribution of a common amino-acid polymorphism in the protease gene (L63P) to this process
were investigated. Using HIV-1 variants resistant to the protease inhibitors saquinavir (G48V ⁄L90M) or
indinavir (A71V ⁄V82T ⁄ I84V), viral replication was studied in the presence or absence of inhibitor and a
mutation at position 63. The initial changes diminished enzyme function of the protease and reduced
replicative capacity for both virus mutants. Addition of the respective inhibitor blocked the wild-type,
but was also able to delay the replication kinetics of either mutant, revealing the limits of resistance.
Importantly, the polymorphic change L63P, although not conferring inhibitor resistance by itself,
provided a signiﬁcant replication beneﬁt to both mutant viruses, particularly under drug pressure, and
may reveal a far-reaching compensating power of polymorphic changes. This may drive evolution and
the directed selection of protease inhibitor-resistant HIV-1 variants, a ﬁnding with signiﬁcant clinical
and diagnostic implications.
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INTRODUCTION
Resistance is one of the important factors limiting
drug efﬁcacy against HIV-1 and can be directly
linked to mutations at speciﬁc amino-acid posi-
tions of the reverse transcriptase (RT) and protease
(PR) proteins, thereby allowing the virus to rep-
licate in the presence of the respective inhibitors.
The high number of replication events during
HIV-1 infection in vivo (an estimated 108)109 new
virions are produced daily) [1,2], along with the
lack of a proofreading function in the RT enzyme
(producing more than one alteration/virus copy
[3]), serves as a powerful driver of spontaneous
genetic diversity in the HIV-1 population (vari-
ants, quasispecies) in the infected host. This
mechanism potentially provides a random pool
of viral variants, which can undergo selection for
drug resistance even during ongoing antiretrovi-
ral therapy. This claim is supported by the
observation that a number of the currently known
mutations associated with resistance to RT or PR
inhibitors have been identiﬁed in virus isolates
from drug-naive patients [4–9].
Recent studies correlate an increased occur-
rence of speciﬁc ‘secondary mutations’ or ‘poly-
morphic changes’ with elevated rates of clinical
treatment failure [6,10,11]. Among the most com-
mon amino-acid polymorphisms in the HIV-1 PR
gene is a leucine-to-proline substitution at residue
63 (L63P), which can occur in >50% of drug-naive
patients [5]. Previous in-vitro studies have exam-
ined the impact of this mutation in the absence of
inhibitor and have demonstrated that it improves
replication of HIV-1 variants [12,13]. It has there-
fore been suggested that L63P may compensate
for the deleterious effects that other resistance-
conferring mutations can have on viral replica-
tion. At present, however, the inﬂuence of L63P
on the replicative capacity of HIV-1 under drug
pressure, a clinically more relevant situation
during therapy, is unknown.
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Mutations accumulated by HIV-1 PR inhibitor
(PI)-resistant variants can signiﬁcantly change the
catalytic activity of the enzyme, and in many cases
its enzymatic activity is diminished, which can
compromise viral replication. Examples have been
found where such a decrease in enzyme function
was restored by other compensatory mutations in
the PR gene, thereby improving replicative capa-
city [12–16]. To date, studies on HIV-1 replication
have often been performed in the absence of drug,
although the replicative capacities of HIV-1 vari-
ants can be affected as soon as drug pressure is
applied [17]. In the present study, a deﬁned
in-vitro system was used to generate several
clinically relevant PI-resistant variants in order
to analyse the effect of speciﬁc drug-selected
mutations on the replicative capacity of the virus
in the presence or absence of drug.
MATERIALS AND METHODS
Cells
The CD4+ HeLa-derived cell line SX22-1 contains an integrated
copy of a silent lacZ reporter gene placed under the control of a
complete HIV-1 long-terminal repeat promoter. The reporter
gene is activated upon expression of HIV-1 Tat protein and
thereby allows viral gene expression to be normalised inde-
pendently of HIV PR or RT activity in transient transfection
experiments [18]. SX22-1 cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (Gibco, Paisley, UK) supplemented
with fetal bovine serum (Gibco) 10% v ⁄v, penicillin–strepto-
mycin (Sigma, St Louis, MO, USA) to 100 U and 100 mg ⁄L,
respectively, and 10 mM HEPES (Sigma). The lymphocytic
CEM-SS cell line was grown in RPMI 1640 medium (Gibco)
supplemented with fetal bovine serum 10% v ⁄v, penicillin–
streptomycin, 200 mM L-glutamine (Sigma), and 50 mM
b-mercaptoethanol (Sigma).
Protease inhibitors
Drug stocks were prepared from commercially available
formulations, kindly provided by M. Battegay (Basel, Switzer-
land), by dissolving the drugs in water or dimethylsulphoxide
to give 10 mM solutions which were stored at ) 20 C. Working
solutions were prepared fresh in cell culture medium.
Generation of molecular clones
Relevant PR mutations were speciﬁcally introduced by PCR-
based mutagenesis into a fully infectious pNL4-3 derivative
with shortened cellular ﬂanks, termed pNL-NF. This clone
possesses a ‘B-consensus’ PR sequence and carries a unique
restriction site immediately downstream from the PR gene,
such as SbfI. This modiﬁcation does not change the efﬁciency of
cleavage of the protease site or the overall replicative capacity
of the new clone (L. Brennan, personal communication). For the
simultaneous introduction of two or more mutations into the
same clone, a sense oligonucleotide carrying the most distal
mutation was used along with a reverse primer that hybridised
downstream from the PR gene. PCR reactions were performed
with Pwo polymerase (Roche Biochemicals, Mannheim, Ger-
many). In order to bring another mutation into the protease
gene, this PCR product itself then served as the reverse primer,
along with a further mutant oligonucleotide mapping in the PR
gene upstream from the ﬁrst mutation. The product of such a
second PCR was gel-puriﬁed and further extended with the
same technique to reach a unique ApaI site in the Gag region of
pNL-NF. The ﬁnal PCR product was double-digested with
ApaI ⁄ SbfI and re-ligated into the complementing vector frag-
ment of the proviral clone pNL-NF. After transformation into
HB101 ⁄ k, the alterations in the reconstituted HIV plasmid
harbouring a mutated PR gene were veriﬁed by standard
dideoxy sequencing on an ABI 310 capillary sequencer
(Applied Biosystems, Warrington, UK).
Cellular processing of pr55 Gag proteins
For DNA transfection in 24-mm culture dishes, 1 · 105 SX22-1
cells were ﬁrst seeded in each well. On the following day, cells
were transfected with 0.2 lg of proviral plasmid DNA of the
respective pNL-NF derivatives using Lipofectamine 2000
(Invitrogen, Basel, Switzerland). After incubation for c. 48 h,
the cell layers were scraped, pelleted by centrifugation and
lysed in Nonidet-P40 0.5% v ⁄v, 10 mM Tris-HCl, pH 7.5. After
a further brief centrifugation step, the supernatant was mixed
with an equal volume of standard SDS-PAGE loading buffer,
boiled for 5 min, electrophoretically separated on SDS-acryla-
mide 12% w ⁄v gels, and electro-transferred to nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany). The
resulting immunoblots were developed with a mouse anti-
HIV-1 p24 monoclonal antibody (Ab 25-57-1; gift of J. Mestan,
Basel, Switzerland) and visualised by enhanced chemilumi-
nescence as recommended by the manufacturer (Amersham,
Little Chalfont, UK).
Studies of viral replication kinetics and
coculture experiments
Puriﬁed plasmid DNA (0.2 g; protocol of Qiagen, Hilden,
Germany) from HIV-1 clones was used to initiate virion
production after transfection into SX22-1 cells. At 48 h post-
transfection, deﬁned mixes of Tat expression-normalised SX22-
1 cells (as speciﬁed in the ﬁgure legends) were used to infect
CEM-SS cells, each in the absence and presence of drug. Viral
cultures were maintained by serially passaging them every
3–4 days in fresh, inhibitor-containing medium. Samples were
collected and used to infect SX22-1 indicator cells. Virus
production was quantiﬁed by measuring Tat-dependent
b-galactosidase production with a colourimetric assay 48 h
after infection, as described previously [18].
Sequencing of variant HIV-1 protease genes
In summary, total RNA was isolated from infected CEM-SS
cultures with a standard protocol (Qiagen) and subjected to
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cDNA synthesis with protease-speciﬁc primers and MULV
reverse transcriptase Superscript II (Invitrogen), used accord-
ing to the manufacturer’s speciﬁcations. Portions of these
reverse transcriptase reactions were ampliﬁed by PCR in a
50-lL volume containing 200 lM dATP, dGTP, dCTP and
dTTP (Sigma), 1 lM of each primer, and 2 U of Hotstar DNA
polymerase (Qiagen) in the manufacturer’s reaction buffer.
PCR products were then puriﬁed and inserted into the pGEM-
T vector (Promega, Madison, WI, USA). Competent HB-101 ⁄ k
cells were transformed with these plasmids and grown on LB
agar plates containing ampicillin. A minimum of ten colonies
was picked for each sample and plasmid DNA prepared
(standard Qiagen plasmid procedure), followed by dideoxy-
sequencing using HIV protease-speciﬁc primers.
RESULTS
Cleavage of intracellular Gag protein in HIV-1
variants with protease mutations
In order to examine the direct, selective inﬂuence
of mutations on enzymatic activity and replicative
capacity in the absence or presence of the corres-
ponding drug, speciﬁc clonal PI-resistant variants
of HIV-1 were engineered. The mutants selected
were the saquinavir-resistant mutant G48V ⁄L90M
[19], the indinavir-resistant mutant A71V ⁄V82T ⁄
I84V [20] and, as a negative control, the inactive
catalytic centre mutant D25N [21].
Plasmid DNA of either the complete, infectious
wild-type (wt), or of isogenic variants carrying
mutated protease genes, was transfected into
SX22-1 cells. Viral protein processingwas analysed
with speciﬁc antibodies that recognise Gag pre-
cursor (pr55) as well as mature (p24) proteins in
cell lysates (Fig. 1). Shifted ratios of pr55 to p24 in
favour of the precursorwere indicative of impaired
HIV protease function. As shown in Fig. 1, levels of
Gag processing similar to those of the wt were
observed for the saquinavir-resistant G48V ⁄L90M
mutant. In contrast, only greatly reduced levels of
processed Gag were detectable for the indinavir-
resistant A71V ⁄V82T ⁄ I84V mutant.
Replicative capacities in the absence or presence
of drug pressure: competition between HIV-1
variants
As the coexistence of several virus variants in a
dynamic balance may be a typical in-vivo situ-
ation during drug therapy, replication was stud-
ied in co-culture competition experiments. This
allowed the ‘relative viral replication ﬁtness’ of a
mutant to be assessed against the wt by deter-
mining changes in their relative proportions after
several cycles of replication. Mixes of wt and
mutants at ratios of 1 : 1 and 10 : 1 were studied.
The replication of the saquinavir-resistant
G48V ⁄L90M mutant was ﬁrst analysed parallel
to or in combination with the wt, in either the
presence or absence of drug (Fig. 2). At a
saquinavir concentration of 10 nM, wt replication
was suppressed (Fig. 2A), but replication kinetics
(time to maximum) did not differ signiﬁcantly
between both viruses in the absence of drug
(Fig. 2B). In competition experiments (Fig. 2C,D)
with different wt ⁄mutant ratios in the absence of
drug pressure, only wt sequences were identiﬁ-
able by subsequent genotypic analysis (Fig. 3).
The disappearance of G48V ⁄L90M indicated a
superior replication capacity of the wt over this
mutant in the absence of drug pressure, thereby
suggesting that the ‘cost’ of acquiring mutations
associated with a high level of resistance to PIs
may be a signiﬁcant impairment of viral ﬁtness.
The fact that both mutants showed a similar
efﬁciency of maturation of viral proteins (Fig. 1;
additional data not shown) suggests that other
compensatory mechanisms play a role. When
saquinavir was present during virus propagation,
only drug-resistant HIV-1 mutants were found in
most of the clones analysed (Fig. 3). In 10 : 1
mixtures, three of the ten clones analysed had lost
the inhibitor-associated mutation at position 48
(Fig. 3), and a spontaneous L63P change was seen
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Fig. 1. Processing of pr55Gag in HeLa CD4+ cells transfect-
ed with an infectious HIV-1 plasmid carrying wild-type
(wt) or mutated PR sequences as indicated. Lysates from
day 2 were analysed for precursor (pr55Gag) and cleavage
(p24Gag) proteins by immunoblotting. D25N is an inactive
catalytic centre mutant with no pr55 processing. Molecular
mass size markers (in kDa) are shown on the left. Lysates
from uninfected cells served as a negative control (‘mock’).
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in one clone (Fig. 3). Similar changes were not
detected in 1 : 1 mixtures of wt and mutant. The
question of whether the new mutations L90M and
G48V ⁄L63P ⁄L90M observed in this experiment
reﬂected spontaneous mutations or DNA recom-
bination events was not further investigated. The
fact that only some of the 10 : 1 samples showed
these alternative mutations argued against a PCR
artifact. Nevertheless, the detection of new muta-
tions may indicate a replicative advantage in the
presence of drug. To test this possibility, CEM-SS
cultures were infected in parallel with viral clones
containing one of the variants L90M, G48V ⁄L90M,
or L63P ⁄G48V ⁄L90M, with monitoring of intra-
cellular pr55Gag-precursor cleavage and viral rep-
lication (Fig. 4). The wt and L90M mutants
showed indistinguishable Gag cleavage proﬁles,
a ﬁnding which is compatible with a similar
catalytic efﬁciency of both proteases, as reported
previously [22]. In contrast, Gag processing in the
G48V ⁄L90M double mutant was reproducibly
delayed, in agreement with a reduced catalytic
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Fig. 2. Replicative ﬁtness of the
G48V ⁄L90M variant in the absence
(solid circles) or presence (open
squares) of saquinavir. Using the
integrated lacZ reporter as indicated
in Materials and Methods, normal-
ised viral supernatants generated in
transfected SX22-1 cells were used to
initiate infections in CEM-SS cells.
Replication proﬁles were obtained
for wt (A), G48V ⁄L90M (B), or
deﬁned mixes at indicated ratios
(C,D). Virus expression is expressed
as cell-associated induction of the
viral long-terminal repeat in arbi-
trary units (X-Gal conversion).
Fig. 3. (A) Sequence comparison after serial passage of deﬁned mixes of wt with the G48V ⁄L90Mmutant in the presence of
saquinavir in the experiments as depicted in Fig. 2. The number of clones with identical sequence is shown on the right (no.
of clones). Amino-acid positions associated with drug resistance are highlighted in grey; dotted lines mark sequence
identity. (B) Number of emerging identical clones from CEM-SS cell infections. Clones were sequenced on day 32 for (1)
and (2), or on day 14 for (3).
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efﬁciency in a cell-free enzymatic system for
protease activity (results not shown). Acquisition
of the L63P substitution yielded a viral protease
(G48V ⁄L63P ⁄L90M) permitting more efﬁcient
Gag cleavage when compared with the corres-
ponding double mutant (G48V ⁄L90M) (Fig. 4A).
When the relative viral replication in the
absence of drug was assessed, the L90M mutant
appeared to replicate with a slightly higher
rate than the wt, and showed a saquinavir
susceptibility identical to that of the wt virus
(Fig. 4B,C). Competition experiments indicated
that the wt and L90M had similar replication
rates, since, after infection with a 1 : 1 mixture,
seven of 13 recovered clones were wt and six were
the L90M mutant (data not shown). In contrast,
the G48V ⁄L90M double mutant showed delayed
replication, but had increased resistance to saqu-
inavir compared with the wt or the L90M-only
mutant (Fig. 4B,C,D). In contrast, when a speciﬁc
additional leucine-to-proline alteration was intro-
duced at position 63, this correlatedwith increased
viral ﬁtness at all tested drug concentrations, with-
out itself affectingdrug resistance (Fig. 4D,E).DNA
sequencing corroborated the identity and integrity
of the respective viral species after completion
of the culture period of 18 days. No additional,
potentially drug-associated mutations were detec-
ted after cell passage (data not shown).
In a similar way, the replication properties of
the clonal indinavir-resistant mutants A71V ⁄
V82T ⁄ I84V and L63P ⁄A71V ⁄V82T ⁄ I84V were ana-
lysed in the absence or presence of drug. The
latter mutant was generated to study the potential
impact of the L63P change in a different muta-
tional context and for a different drug (Fig. 5). In
the presence of 50 nM indinavir, both mutants
replicated with markedly delayed kinetics com-
pared to replication in the absence of indinavir
(Fig. 5B,C), while virus sequencing (Fig. 3B)
revealed the genetic integrity of the respective
mutants under drug pressure. An indistinguish-
able replication proﬁle for both mutants demon-
strated that the only genetic difference, mutation
L63P, did not provide any replication advantage
when no drug was present (Fig. 5B,C), and
sequencing of wt–mutant mixes under this
condition identiﬁed only wt sequences (Fig. 3B).
Similar results were obtained in infections of
either CEM-SS cells or primary peripheral blood
Fig. 4. Replicative ﬁtness of the pro-
tease variants L90M, G48V ⁄L90M
and L63P ⁄G48V ⁄L90M in the
absence and presence of drug, using
cell-free virus infections of CEM-SS
cells. (A) Virus expression was
analysed on days 6, 10 and 14 post-
infection with a p24Gag-speciﬁc anti-
body. Precursor (pr55) and mature
(p24) proteins are marked, and
molecular size markers (kDa) are
shown on the left. (B–E) Virus rep-
lication proﬁles for wt and mutants
are shown as functions of time and
were obtained in the absence (solid
circles) or presence of the indicated
saquinavir concentrations. Viral
replication (in arbitrary units) was
quantiﬁed via X-Gal conversion.
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mononuclear cells (data not shown). In contrast,
when the inhibitor was present during the infec-
tions, the L63P ⁄A71V ⁄V82T ⁄ I84V mutant repli-
cated with much higher efﬁciency than the
A71V ⁄V82T ⁄ I84V mutant, and shifted the peak
of expression from >32 days to day 17 (Fig. 5B,C).
This ﬁnding demonstrated that, under drug pres-
sure, the L63P change itself is able to partially
restore the delayed replication kinetics of the
A71V ⁄V82T ⁄ I84V mutant, a ﬁnding that corre-
lates with the role of L63P seen for the G48V ⁄
L90M mutant.
DISCUSSION
Virus replication in the HIV-infected patient is
inﬂuenced by a complex array of patient-speciﬁc
factors driving immunological responses and
drug metabolism, and by the potency of an
antiretroviral therapy regimen. It has been shown
that speciﬁc point mutations in the key enzymes of
HIV correlate with a modulation of virus replica-
tive capacity [14,15,23]. This is likely to reﬂect a
penalty for the acquisition of resistance to a potent
drug, and could help explain cases where sus-
tained clinical beneﬁt is observed despite the
presence of resistance-associated mutations
[24,25]. Since the presence of therapeutic drugs
in the circulation is now the standard clinical
situation, the current study investigated in-vitro
HIV-1 infections under high, but not sterilising,
drug pressure. The results demonstrated that
resistance is not simply the all-or-none ability of
a virus to replicate in the presence of inhibitor, but
also has to involve virus replicative capacity.
However, Mammano et al. [17] have shown an
inverse link between HIV ﬁtness and drug con-
centration.
Ongoing virus replication in the patient is likely
to be the basis for the establishment of sequence
heterogeneity, and thereby mixed virus popula-
tions. Such generation of coexisting variants of
HIV probably occurs preferentially in periods
when the virus is least restricted by drug pres-
sure, e.g., after drug failure, during therapy
interruption, or in the non-compliant patient
Fig. 5. Replicative ﬁtness of the
two indinavir-resistant variants in
the absence (solid circles) or pres-
ence (open squares) of indinavir in
a co-culture of expression-normal-
ised, transfected human cells mixed
with CEM-SS cells. Replication
proﬁles of individual viruses
(A–C) or of 1 : 1 mixtures of wt
with A71V ⁄V82T ⁄ I84V (D) or
with L63P ⁄A71V ⁄V82T ⁄ I84V (E)
are plotted as a function of time
post co-cultivation. Virus replica-
tion was assessed via cell-associ-
ated X-Gal conversion.
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[26–28]. However, these situations would not
yield just one new virus variant, so that each
new generation of virions will enter a continuous
selection process for optimal adaptation to the
current (therapeutic) situation. Even the limited
setting of this study was able to demonstrate the
appearance and selection of novel therapy-rele-
vant HIV variants with mutant proteases (Fig. 3).
A new mutant with only an L90M substitution
did not gain resistance compared to the wt, but it
possessed a higher replicative capacity than the
initial G48V ⁄L90M double mutant [19,29]. The
precise reason remains to be elucidated, but
altered protein folding and stability might have
contributed. The second spontaneously occurring
L63P mutation fully compensated for the
impaired replication of the double G48V ⁄L90M
mutation, but without permitting the resulting
virus to replicate at higher drug concentrations.
These data complement those on drug-free infec-
tions, for which it has been reported that L63P
itself provides a replication improvement for
several HIV-1 variants [12,13]. Although some
investigators have not found any appreciable gain
in the level of resistance for G48V ⁄L63P ⁄L90M
[30], the frequent appearance of the identical
mutations in different patients during sub-
optimal monotherapy with ritonavir in vivo [31],
or during failing saquinavir treatment [32], may
be explained by superior replication of the
mutated virus. Extending the data to the indina-
vir ⁄ ritonavir-resistant mutant A71V ⁄V82T ⁄ I84V
links a viral growth advantage more tightly to
drug treatment; in the absence of drug, the L63P
substitution failed to provide any replication
advantage to the A71V ⁄V82T ⁄ I84V-mutant (Fig.
5B,C), but it strongly enhanced viral replicative
ﬁtness in the presence of drug. These data
correlate with the observed higher rate of HIV-1
replication in treated patients when the L63P
substitution is present [12,33].
Although undetermined at this point, it is
possible that the observed difference between
the two model mutants G48V ⁄L90M and
A71V ⁄V82T ⁄ I84V with regard to their replication
in the absence or presence of drug could be
caused by the fact that a severe functional
impairment of protease (e.g., in the A71V ⁄V82T ⁄
I84V situation) could make the mutant enzyme
the replication rate-limiting step, thus slowing
virus replication even without any drug pressure
being applied.
In summary, investigation of in-vitro replica-
tion of PI-resistant HIV-1 mutants under thera-
peutic drug pressure is suitable for assessing viral
replicative ﬁtness in the presence of therapeutic
drugs, and could be of critical clinical relevance. It
is possible to characterise viral parameters that
may be useful for improving the prediction of
success of a therapeutic regimen, which in turn
could inﬂuence decisions about continuing or
changing regimens [34,35]. Extended studies on a
broader range of virus mutants will be required to
link in-vitro data on speciﬁc mutational resistance
patterns and viral ﬁtness with therapeutic failure
and patient outcome.
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